How Strong BRUKINSA Sales and Patent Resolution at BeOne Medicines (ONC) Have Changed Its Investment Story

BeOne Medicines Ltd. recently reported third quarter 2025 results, achieving US$1.41 billion in revenue and US$124.84 million in net income, a shift from a net loss during the same period last year, attributed to a very large increase in sales of its core oncology therapy, BRUKINSA. The company also raised full-year 2025 revenue guidance and resolved a significant patent dispute regarding BRUKINSA, further strengthening operational confidence and its competitive position. We'll examine how BeOne's raised guidance and BRUKINSA-driven profitability impact the company's investment narrative and future outlook.

These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

BeOne Medicines Investment Narrative Recap

To own shares of BeOne Medicines today, you need to believe in the company’s ability to deliver sustained profit growth by expanding its oncology franchise, particularly through BRUKINSA, while managing heavy revenue concentration risks. The jump to profitability and raised 2025 revenue guidance are clear positives for the core oncology catalyst, and the resolution of the BRUKINSA patent suit reduces one immediate threat, but high single-product reliance remains the most important risk for the near term.

Among the recent announcements, the resolution of the patent dispute with Pharmacyclics stands out as directly relevant to the company’s main short-term catalyst. With all patent claims against BRUKINSA invalidated and no appeal, BeOne Medicines removes a legal overhang, helping to reinforce operational stability and support management’s higher full-year outlook, especially as BRUKINSA sales continue to power results.

However, despite these gains, investors should still be aware of how future regulatory policy changes could impact pricing flexibility and margins if...

Read the full narrative on BeOne Medicines (it's free!)

BeOne Medicines' outlook points to $7.6 billion in revenue and $1.3 billion in earnings by 2028. This is based on analysts forecasting an 18.6% annual revenue growth rate and an increase in earnings of about $1.48 billion from the current level of -$177.6 million.

Uncover how BeOne Medicines' forecasts yield a $382.29 fair value, a 19% upside to its current price.

Exploring Other PerspectivesONC Community Fair Values as at Nov 2025

Simply Wall St Community members provided five fair value estimates for BeOne Medicines ranging from US$250 to US$786,065, capturing a broad spectrum of future expectations. While many anticipate long-term growth in BeOne’s core oncology business, ongoing product concentration risk remains a factor that could influence both near-term performance and longer-term value, explore these differing views to see where you stand.

Story continues

Explore 5 other fair value estimates on BeOne Medicines - why the stock might be worth over 2x more than the current price!

Build Your Own BeOne Medicines Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

A great starting point for your BeOne Medicines research is our analysis highlighting 5 key rewards that could impact your investment decision. Our free BeOne Medicines research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate BeOne Medicines' overall financial health at a glance.

Seeking Other Investments?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

Rare earth metals are the new gold rush. Find out which 35 stocks are leading the charge. This technology could replace computers: discover 28 stocks that are working to make quantum computing a reality. Outshine the giants: these 24 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ONC.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View comments